Clinuvel Pharmaceuticals has received final regulatory guidance from the European Medicines Agency on the design of its Phase III vitiligo trial, clearing the path for a pivotal study that could determine the company’s commercial prospects in a major European market. The EMA’s scientific advice, delivered after more than 12 months of dialogue and two formal submissions, provides detailed direction on how the regulator will evaluate evidence of efficacy and safety for SCENESSE as a systemic vitiligo treatment.
The CUV107 study will involve 300 patients comparing SCENESSE with adjunct narrowband ultraviolet B therapy against NB-UVB monotherapy alone, with recruitment expected to commence in the second half of 2026. The trial’s primary endpoint will be T-VASI50, a standardised measure of vitiligo lesion coverage, assessed through central photographic review. The EMA’s embrace of photographic evidence as a core evaluation method represents a significant win for CLINUVEL, as it explicitly recognised that visual demonstration of pigmentation improvement carries meaningful weight in regulatory assessment.
The EMA’s regulatory approach emphasises “totality of evidence” rather than reliance on a single primary endpoint, meaning efficacy and safety data from CUV107 will be evaluated alongside results from CLINUVEL’s existing vitiligo studies. The regulator has indicated that patient reported outcomes will play a meaningful role in the final evaluation, with five distinct patient and physician surveys integrated into CUV107 to capture these perspectives. This holistic framework reduces the pressure on any single trial to demonstrate overwhelming efficacy and suggests the EMA recognises the subjective and objective dimensions of vitiligo treatment outcomes.
A notable element of the EMA’s guidance concerns patient population strategy. The regulator advised that patients with darker skin tones, classified as Fitzpatrick IV through VI, would likely benefit most from systemic treatment given the heightened visual contrast between affected and unaffected skin. This guidance is relevant to market sizing and commercial launch strategy, as it identifies a priority patient group for initial approval and market penetration.
For investors, the receipt of final scientific advice substantially de-risks the regulatory pathway in Europe. The extended negotiation process with the EMA’s Scientific Advice Working Party and Committee for Medicinal Products for Human Use confirms that the trial design aligns with regulatory expectations. The explicit commitment to a “totality of evidence” framework and acknowledgment of photographic assessment methodology reduce the prospect of unexpected regulatory objections during the eventual marketing authorisation review. CLINUVEL now moves forward with confidence that the trial will be evaluated against criteria already agreed with the regulator.
The critical milestones ahead include trial initiation in H2 2026 and eventual completion of the 300-patient CUV107 study, followed by data analysis and marketing authorisation submission. Investors should monitor recruitment pace and interim safety data closely, as any delays or safety concerns could impact the commercial timeline. This announcement has been declared price sensitive and flagged as material by the ASX.
View the full ASX announcement (PDF)
About Clinuvel Pharmaceuticals Limited (ASX: CUV)
Clinuvel Pharmaceuticals Limited is an Australian specialty pharmaceutical company headquartered in Melbourne that develops and commercializes treatments for genetic, metabolic, systemic, and life-threatening disorders. Its lead product, SCENESSE (afamelanotide 16mg), is approved for preventing phototoxicity in patients with erythropoietic protoporphyria and is available in Europe, the United States, Israel, and Australia. The company maintains a pipeline of additional therapies targeting neurological and degenerative disorders.
If you would like to discuss this announcement or how it might affect your portfolio, request a callback or call us on 1300 889 603.
